BridGene Biosciences Expands Collaboration With Galapagos NV, Eligible To Receive Up To $159M In Total Payments; Partnership Focuses On Discovery Of Highly Selective Oral SMARCA2 PROTAC
Portfolio Pulse from Benzinga Newsdesk
BridGene Biosciences has expanded its collaboration with Galapagos NV, making BridGene eligible to receive up to $159 million in total payments. The partnership aims to discover highly selective oral SMARCA2 PROTAC.
August 01, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Galapagos NV has expanded its collaboration with BridGene Biosciences, potentially leading to up to $159 million in payments to BridGene. The partnership focuses on the discovery of highly selective oral SMARCA2 PROTAC.
The expanded collaboration with BridGene Biosciences could lead to significant advancements in the discovery of selective oral SMARCA2 PROTAC, potentially enhancing Galapagos NV's product pipeline and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90